<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE rdf:RDF [
	<!ENTITY cmns-av "https://www.omg.org/spec/Commons/AnnotationVocabulary/">
	<!ENTITY cmns-cds "https://www.omg.org/spec/Commons/CodesAndCodeSets/">
	<!ENTITY cmns-cls "https://www.omg.org/spec/Commons/Classifiers/">
	<!ENTITY cmns-cmp "https://www.omg.org/spec/Commons/Composites/">
	<!ENTITY cmns-col "https://www.omg.org/spec/Commons/Collections/">
	<!ENTITY cmns-cxtdsg "https://www.omg.org/spec/Commons/ContextualDesignators/">
	<!ENTITY cmns-doc "https://www.omg.org/spec/Commons/Documents/">
	<!ENTITY cmns-dsg "https://www.omg.org/spec/Commons/Designators/">
	<!ENTITY cmns-ge-euj "https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/">
	<!ENTITY cmns-id "https://www.omg.org/spec/Commons/Identifiers/">
	<!ENTITY cmns-org "https://www.omg.org/spec/Commons/Organizations/">
	<!ENTITY cmns-prd "https://www.omg.org/spec/Commons/ProductsAndServices/">
	<!ENTITY cmns-pts "https://www.omg.org/spec/Commons/PartiesAndSituations/">
	<!ENTITY cmns-qtu "https://www.omg.org/spec/Commons/QuantitiesAndUnits/">
	<!ENTITY cmns-ra "https://www.omg.org/spec/Commons/RegistrationAuthorities/">
	<!ENTITY cmns-rga "https://www.omg.org/spec/Commons/RegulatoryAgencies/">
	<!ENTITY cmns-strcol "https://www.omg.org/spec/Commons/StructuredCollections/">
	<!ENTITY cmns-txt "https://www.omg.org/spec/Commons/TextDatatype/">
	<!ENTITY dct "http://purl.org/dc/terms/">
	<!ENTITY doc-ema "https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#">
	<!ENTITY doc-fda "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#">
	<!ENTITY doco "http://purl.org/spar/doco/">
	<!ENTITY idmp-chg "https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/">
	<!ENTITY idmp-ctcae "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/CommonTerminologyCriteriaForAdverseEvents/">
	<!ENTITY idmp-doco "https://spec.pistoiaalliance.org/idmp/ontology/EXT/DocumentComponents/">
	<!ENTITY idmp-dtp "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO21090-HarmonizedDatatypes/">
	<!ENTITY idmp-eura "https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/">
	<!ENTITY idmp-eurga "https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/">
	<!ENTITY idmp-meddra "https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/">
	<!ENTITY idmp-mprd "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/">
	<!ENTITY idmp-nara "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegistrationAuthorities/">
	<!ENTITY idmp-narga "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegulatoryAgencies/">
	<!ENTITY idmp-phprd "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11616-PharmaceuticalProducts/">
	<!ENTITY idmp-plu "https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/">
	<!ENTITY idmp-ra "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/">
	<!ENTITY idmp-snomed "https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/">
	<!ENTITY idmp-spor "https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/SubstancesProductsOrganisationsReferentials/">
	<!ENTITY idmp-sub "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/">
	<!ENTITY idmp-ucum "https://spec.pistoiaalliance.org/idmp/ontology/EXT/Extensions/UnifiedCodeForUnitsOfMeasure/">
	<!ENTITY idmp-uom "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11240-UnitsOfMeasurement/">
	<!ENTITY lcc-3166-1 "https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/">
	<!ENTITY lcc-639-1 "https://www.omg.org/spec/LCC/Languages/ISO639-1-LanguageCodes/">
	<!ENTITY lcc-cr "https://www.omg.org/spec/LCC/Countries/CountryRepresentation/">
	<!ENTITY lcc-lr "https://www.omg.org/spec/LCC/Languages/LanguageRepresentation/">
	<!ENTITY mvf "https://www.omg.org/spec/MVF/MultipleVocabularyFacility/">
	<!ENTITY mvf-trm "https://www.omg.org/spec/MVF/ISO1087-VocabularyForTermsAndDefinitions/">
	<!ENTITY owl "http://www.w3.org/2002/07/owl#">
	<!ENTITY po "http://purl.org/spar/po/">
	<!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#">
	<!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#">
	<!ENTITY skos "http://www.w3.org/2004/02/skos/core#">
	<!ENTITY snomed "https://lookup.snomedtools.org/">
	<!ENTITY xsd "http://www.w3.org/2001/XMLSchema#">
]>
<rdf:RDF xml:base="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/"
	xmlns:cmns-av="https://www.omg.org/spec/Commons/AnnotationVocabulary/"
	xmlns:cmns-cds="https://www.omg.org/spec/Commons/CodesAndCodeSets/"
	xmlns:cmns-cls="https://www.omg.org/spec/Commons/Classifiers/"
	xmlns:cmns-cmp="https://www.omg.org/spec/Commons/Composites/"
	xmlns:cmns-col="https://www.omg.org/spec/Commons/Collections/"
	xmlns:cmns-cxtdsg="https://www.omg.org/spec/Commons/ContextualDesignators/"
	xmlns:cmns-doc="https://www.omg.org/spec/Commons/Documents/"
	xmlns:cmns-dsg="https://www.omg.org/spec/Commons/Designators/"
	xmlns:cmns-ge-euj="https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/"
	xmlns:cmns-id="https://www.omg.org/spec/Commons/Identifiers/"
	xmlns:cmns-org="https://www.omg.org/spec/Commons/Organizations/"
	xmlns:cmns-prd="https://www.omg.org/spec/Commons/ProductsAndServices/"
	xmlns:cmns-pts="https://www.omg.org/spec/Commons/PartiesAndSituations/"
	xmlns:cmns-qtu="https://www.omg.org/spec/Commons/QuantitiesAndUnits/"
	xmlns:cmns-ra="https://www.omg.org/spec/Commons/RegistrationAuthorities/"
	xmlns:cmns-rga="https://www.omg.org/spec/Commons/RegulatoryAgencies/"
	xmlns:cmns-strcol="https://www.omg.org/spec/Commons/StructuredCollections/"
	xmlns:cmns-txt="https://www.omg.org/spec/Commons/TextDatatype/"
	xmlns:dct="http://purl.org/dc/terms/"
	xmlns:doc-ema="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf#"
	xmlns:doc-fda="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf#"
	xmlns:doco="http://purl.org/spar/doco/"
	xmlns:idmp-chg="https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/"
	xmlns:idmp-ctcae="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/CommonTerminologyCriteriaForAdverseEvents/"
	xmlns:idmp-doco="https://spec.pistoiaalliance.org/idmp/ontology/EXT/DocumentComponents/"
	xmlns:idmp-dtp="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO21090-HarmonizedDatatypes/"
	xmlns:idmp-eura="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/"
	xmlns:idmp-eurga="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/"
	xmlns:idmp-meddra="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/"
	xmlns:idmp-mprd="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/"
	xmlns:idmp-nara="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegistrationAuthorities/"
	xmlns:idmp-narga="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegulatoryAgencies/"
	xmlns:idmp-phprd="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11616-PharmaceuticalProducts/"
	xmlns:idmp-plu="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/"
	xmlns:idmp-ra="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/"
	xmlns:idmp-snomed="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/"
	xmlns:idmp-spor="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/SubstancesProductsOrganisationsReferentials/"
	xmlns:idmp-sub="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/"
	xmlns:idmp-ucum="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Extensions/UnifiedCodeForUnitsOfMeasure/"
	xmlns:idmp-uom="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11240-UnitsOfMeasurement/"
	xmlns:lcc-3166-1="https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/"
	xmlns:lcc-639-1="https://www.omg.org/spec/LCC/Languages/ISO639-1-LanguageCodes/"
	xmlns:lcc-cr="https://www.omg.org/spec/LCC/Countries/CountryRepresentation/"
	xmlns:lcc-lr="https://www.omg.org/spec/LCC/Languages/LanguageRepresentation/"
	xmlns:mvf="https://www.omg.org/spec/MVF/MultipleVocabularyFacility/"
	xmlns:mvf-trm="https://www.omg.org/spec/MVF/ISO1087-VocabularyForTermsAndDefinitions/"
	xmlns:owl="http://www.w3.org/2002/07/owl#"
	xmlns:po="http://purl.org/spar/po/"
	xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
	xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
	xmlns:skos="http://www.w3.org/2004/02/skos/core#"
	xmlns:snomed="https://lookup.snomedtools.org/"
	xmlns:xsd="http://www.w3.org/2001/XMLSchema#">
	
	<owl:Ontology rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/PluvictoExample/">
		<rdfs:label>Novartis&apos; PLUVICTO® Example Ontology</rdfs:label>
		<dct:abstract>This ontology provides an example for some of the data related to the substance, amlodipine, to demonstrate substance and basis of strength representation.</dct:abstract>
		<dct:description>Example using Pluvicto focusing on clinical particulars with multiple adverse events referenced from content in the EMA and FDA patient information documents</dct:description>
		<dct:license rdf:datatype="&xsd;anyURI">https://opensource.org/licenses/MIT</dct:license>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Extensions/UnifiedCodeForUnitsOfMeasure/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11240-UnitsOfMeasurement/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO21090-HarmonizedDatatypes/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/CommonTerminologyCriteriaForAdverseEvents/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/NorthAmericanRegulatoryAgencies/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/AnnotationVocabulary/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Classifiers/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Collections/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/ContextualDesignators/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Designators/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Documents/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Identifiers/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Organizations/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/PartiesAndSituations/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/ProductsAndServices/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/QuantitiesAndUnits/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/RegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/RegulatoryAgencies/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/StructuredCollections/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/TextDatatype/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Countries/CountryRepresentation/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Languages/ISO639-1-LanguageCodes/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Languages/LanguageRepresentation/"/>
		<owl:versionIRI rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/20230701/Examples/PluvictoExample/"/>
		<idmp-chg:hasMaturityLevel rdf:resource="&idmp-chg;Informative"/>
		<cmns-av:copyright>Copyright (c) 2022-2023 EDM Council, Inc.</cmns-av:copyright>
		<cmns-av:copyright>Copyright (c) 2022-2023 Pistoia Alliance, Inc.</cmns-av:copyright>
		<cmns-av:usageNote>This example is for illustration purposes only. The data provided may not be up-to-date, and in some cases, &apos;dummy&apos; data has been included. The product information included here shall not be used for any other purpose than for educational purposes regarding the IDMP-O implementation.</cmns-av:usageNote>
	</owl:Ontology>
	
	<owl:NamedIndividual rdf:about="https://lookup.snomedtools.org/">
		<rdf:type rdf:resource="&idmp-dtp;ControlledVocabulary"/>
		<rdf:type rdf:resource="&cmns-cds;CodeSet"/>
		<rdf:type rdf:resource="&cmns-ra;Registry"/>
		<rdfs:label>SNOMED-CT Concept Lookup</rdfs:label>
		<skos:definition>SNOMED-CT API for accessing concepts registered in SNOMED CT</skos:definition>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Lutetium177LuVipivotideTeraxetan">
		<rdf:type rdf:resource="&idmp-sub;ChemicalSubstance"/>
		<rdfs:label>lutetium (177Lu) vipivotide tetraxetan</rdfs:label>
		<cmns-dsg:hasName rdf:resource="&idmp-plu;Lutetium177LuVipivotideTeraxetan-CommonName"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Lutetium177LuVipivotideTeraxetan-CommonName">
		<rdf:type rdf:resource="&idmp-sub;SubstanceName"/>
		<cmns-cls:isClassifiedBy rdf:resource="&idmp-sub;SubstanceNameClassifier-CommonName"/>
		<cmns-txt:hasTextValue>lutetium (177Lu) vipivotide tetraxetan</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;Lutetium177LuVipivotideTeraxetanAsActiveIngredientInPluvicto">
		<rdf:type rdf:resource="&idmp-sub;ActiveIngredient"/>
		<rdfs:label>lutetium (177Lu) vipivotide tetraxetan as active ingredient in Pluvicto</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-plu;Lutetium177LuVipivotideTeraxetan"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedMedicinalProduct"/>
		<rdfs:label>Pluvicto AMP (EMA)</rdfs:label>
		<idmp-mprd:hasAuthorization rdf:resource="&idmp-plu;PluvictoMarketingAuthorizationByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-Contraindication-Hypersensitivity">
		<rdf:type rdf:resource="&idmp-mprd;Contraindication"/>
		<rdfs:label>Pluvicto AMP (EMA) - contraindication - hypersensitivity</rdfs:label>
		<idmp-mprd:hasContraindicationText>
			<owl:NamedIndividual>
				<rdf:type rdf:resource="&idmp-mprd;ContraindicationText"/>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6.1"/>
				<cmns-txt:hasTextValue>Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</cmns-txt:hasTextValue>
			</owl:NamedIndividual>
		</idmp-mprd:hasContraindicationText>
		<idmp-mprd:isContraindicationFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-TherapeuticIndication-Text">
		<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndicationText"/>
		<rdfs:label>Pluvicto AMP (EMA) -  therapeutic indication - text</rdfs:label>
		<cmns-txt:hasTextValue>Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-TherapeuticIndication-TreatmentOfPSMACancer">
		<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndication"/>
		<rdfs:label>Pluvicto AMP (EMA) - therapeutic indication - treatment of PSMA cancer</rdfs:label>
		<idmp-mprd:hasIndicationAsDiseaseSymptomProcedure rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ProstateCancer"/>
		<idmp-mprd:hasTargetPopulation rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-TherapeuticIndication-TreatmentOfPSMACancer-TargetPopulation-Adults"/>
		<idmp-mprd:hasTherapeuticIndicationText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-TherapeuticIndication-Text"/>
		<idmp-mprd:isTherapeuticIndicationFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-TherapeuticIndication-TreatmentOfPSMACancer-TargetPopulation-Adults">
		<rdf:type rdf:resource="&idmp-mprd;TargetPopulation"/>
		<rdfs:label>Pluvicto AMP (EMA) -  therapeutic indication - treatment of PSMA cancer - target population - adults</rdfs:label>
		<cmns-cls:isClassifiedBy rdf:resource="https://spor.ema.europa.eu/rmswi/lists/100000000001/terms/200000002250"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-ASTOrALTElevation">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - AST or ALT elevation</rdfs:label>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AlanineAminotransferaseIncreased"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AspartateAminotransferaseIncreased"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-ASTOrALTElevation-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-ASTOrALTElevation-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>AST or ALT elevation | AST or ALT &gt;5 times ULN in the absence of liver metastases</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade2">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - anaemia, thrombocytopenia, neutropenia, pancytopenia - grade 2</rdfs:label>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade2"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Anaemia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Leukopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Neutropenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Pancytopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Thrombocytopenia"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade2-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade2-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Anaemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia | Grade 2</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade3">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - anaemia, thrombocytopenia, neutropenia, pancytopenia - grade 3</rdfs:label>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Anaemia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Leukopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Neutropenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Pancytopenia"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Thrombocytopenia"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade3-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-AnaemiaThrombocytopeniaLeukopeniaNeutropeniaPancytopenia-Grade3-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Anaemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia | Grade 3</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-DecreasedAppetite">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) - undesirable effect- decreased appetite</rdfs:label>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DecreasedAppetite"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-DecreasedAppetite-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductEU"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-DecreasedAppetite-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>???</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-DryMouth">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - dry mouth</rdfs:label>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DryMouth"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-DryMouth-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-DryMouth-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Dry mouth | Grade 3</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-ElectrolyteOrMetabolicAbnormalities">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - electrolyte or metabolic abnormalities</rdfs:label>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade2"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ElectrolyteAbnormality"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/MetabolicDisorder"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-ElectrolyteOrMetabolicAbnormalities-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-ElectrolyteOrMetabolicAbnormalities-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Electrolyte or metabolic abnormalities | Grade ≥2</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Fatigue-Grade3">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - fatigue - grade 3</rdfs:label>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fatigue"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Fatigue-Grade3-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Fatigue-Grade3-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Fatigue | Grade ≥3</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-FractureInWeightBearingBones">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - fracture in weight bearing bones</rdfs:label>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fracture"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-FractureInWeightBearingBones-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-FractureInWeightBearingBones-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Fracture in weight-bearing bones</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Hypersensitivity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) - undesirable effect- hypersensitivity</rdfs:label>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Hypersensitivity"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Hypersensitivity-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductEU"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Hypersensitivity-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6.1"/>
		<cmns-txt:hasTextValue>Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Myelosuppression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) - undesirable effect- myelosuppression</rdfs:label>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Myelosuppression"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Myelosuppression-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductEU"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-Myelosuppression-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia,
						and neutropenia. In the VISION study, Grade 3 or 4 decreased hemoglobin (15%), decreased platelets(9%), decreased
						leukocytes(7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO. Grade ≥ 3 pancytopenia
						occurred in 1.1% (which includes two fatal events) in patients treated with PLUVICTO. Two deaths(0.4%) due to
						intracranial hemorrhage and subdural hematoma in association with thrombocytopenia were observed in patients who
						received PLUVICTO. One death due to sepsis and concurrent neutropenia was observed in patients who received
						PLUVICTO.</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-NonHaematologicalToxicity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - non-haematological toxicity</rdfs:label>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade2"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade3"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade4"/>
		<idmp-mprd:hasSymptomConditionEffectClassification rdf:resource="&idmp-ctcae;CTCAE-Grade5"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-NonHaematologicalToxicity-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-NonHaematologicalToxicity-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Non-haematological toxicity (clinically significant, not otherwise stated) in Grade ≥2</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-RenalToxicity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - renal toxicity</rdfs:label>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ToxicityRenal"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-RenalToxicity-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-RenalToxicity-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Renal toxicity</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-SpinalCordCompression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffect"/>
		<rdfs:label>Pluvicto AMP (EMA) -  undesirable effect - spinal cord compression</rdfs:label>
		<idmp-mprd:hasUndesirableEffectAsSymptomConditionEffect rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/SpinalCordCompression"/>
		<idmp-mprd:hasUndesirableEffectText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-SpinalCordCompression-Text"/>
		<idmp-mprd:isUndesirableEffectOf rdf:resource="&idmp-plu;PluvictoMedicinalProductInEU"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA-UndesirableEffect-SpinalCordCompression-Text">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectText"/>
		<cmns-txt:hasTextValue>Spinal cord compression</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedMedicinalProduct"/>
		<rdfs:label>Pluvicto AMP (FDA)</rdfs:label>
		<idmp-mprd:hasAuthorization rdf:resource="&idmp-plu;PluvictoMarketingAuthorizationByFDA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA-TherapeuticIndication">
		<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndication"/>
		<rdfs:label>Pluvicto AMP (FDA) -  therapeutic indication</rdfs:label>
		<idmp-mprd:hasIndicationAsDiseaseSymptomProcedure rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/concept/MalignantTumorOfProstateDisorder"/>
		<idmp-mprd:hasTherapeuticIndicationText rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA-TherapeuticIndication-Text"/>
		<idmp-mprd:isTherapeuticIndicationFor rdf:resource="&idmp-plu;PluvictoMedicinalProductInUS"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA-TherapeuticIndication-Text">
		<rdf:type rdf:resource="&idmp-mprd;TherapeuticIndicationText"/>
		<rdfs:label>Pluvicto AMP (FDA) -  therapeutic indication - text</rdfs:label>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-1-Text"/>
		<cmns-txt:hasTextValue>PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMarketingAuthorizationByEMA">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorization"/>
		<rdfs:label>Pluvicto marketing authorization by EMA</rdfs:label>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-eurga;EuropeanMedicinesAgency"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMarketingAuthorizationByFDA">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorization"/>
		<rdfs:label>Pluvicto marketing authorization by FDA</rdfs:label>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-narga;UnitedStatesFoodAndDrugAdministration"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMedicinalProductInEU">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>PLUVICTO® medicinal product in EU</rdfs:label>
		<cmns-dsg:hasName>
			<idmp-mprd:MedicinalProductName>
				<cmns-txt:hasTextValue>Pluvicto 1,000 MBq/mL solution for injection/infusion</cmns-txt:hasTextValue>
			</idmp-mprd:MedicinalProductName>
		</cmns-dsg:hasName>
		<cmns-pts:playsRole rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByEMA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-plu;PluvictoMedicinalProductInUS">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>PLUVICTO® medicinal product in US</rdfs:label>
		<cmns-dsg:hasName>
			<idmp-mprd:MedicinalProductName>
				<cmns-txt:hasTextValue>PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use</cmns-txt:hasTextValue>
			</idmp-mprd:MedicinalProductName>
		</cmns-dsg:hasName>
		<cmns-pts:playsRole rdf:resource="&idmp-plu;PluvictoAuthorizedMedicinalProductByFDA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AlanineAminotransferaseIncreased">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Alanine aminotransferase increased</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10001551"/>
		<cmns-txt:hasTextValue>Alanine aminotransferase increased</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Anaemia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Anaemia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10002034"/>
		<cmns-txt:hasTextValue>Anaemia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/AspartateAminotransferaseIncreased">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Aspartate aminotransferase increased</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10003481"/>
		<cmns-txt:hasTextValue>Aspartate aminotransferase increased</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DecreasedAppetite">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Decreased appetite</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10061428"/>
		<cmns-txt:hasTextValue>Decreased appetite</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/DryMouth">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Dry Mouth</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10013781"/>
		<cmns-txt:hasTextValue>Dry Mouth</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ElectrolyteAbnormality">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Electrolyte abnormality</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10014410"/>
		<cmns-txt:hasTextValue>Electrolyte abnormality</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fatigue">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Fatigue</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10016256"/>
		<cmns-txt:hasTextValue>Fatigue</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Fracture">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Fracture</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10017076"/>
		<cmns-txt:hasTextValue>Fracture</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Hypersensitivity">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Hypersensitivity</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10020751"/>
		<cmns-txt:hasTextValue>Hypersensitivity</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Leukopenia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Leukopenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10024384"/>
		<cmns-txt:hasTextValue>Leukopenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/MetabolicDisorder">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Metabolic disorder</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10058097"/>
		<cmns-txt:hasTextValue>Metabolic disorder</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Myelosuppression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Myelosuppression</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10028584"/>
		<cmns-txt:hasTextValue>Myelosuppression</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Neutropenia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Neutropenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10029354"/>
		<cmns-txt:hasTextValue>Neutropenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Pancytopenia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Pancytopenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10033661"/>
		<cmns-txt:hasTextValue>Pancytopenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ProstateCancer">
		<rdf:type rdf:resource="&idmp-mprd;IndicationAsDiseaseSymptomProcedure"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRAPreferredTerm"/>
		<rdfs:label>Prostate cancer</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10060862"/>
		<cmns-txt:hasTextValue>Prostate cancer</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/RedBloodCellCountLow">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Red blood cell count low</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10038156"/>
		<cmns-txt:hasTextValue>Red blood cell count low</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/SpinalCordCompression">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Spinal cord compression</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10041549"/>
		<cmns-txt:hasTextValue>Spinal cord compression</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/Thrombocytopenia">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Thrombocytopenia</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10043554"/>
		<cmns-txt:hasTextValue>Thrombocytopenia</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/LLT/ToxicityRenal">
		<rdf:type rdf:resource="&idmp-mprd;UndesirableEffectAsSymptomConditionEffect"/>
		<rdf:type rdf:resource="&idmp-meddra;MedDRALowestLevelTerm"/>
		<rdfs:label>Toxicity renal</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10044258"/>
		<cmns-txt:hasTextValue>Toxicity renal</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10001551">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10001551</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10002034">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10002034</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10003481">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10003481</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10013781">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10013781</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10014410">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10014410</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10016256">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10016256</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10017076">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10017076</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10020751">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10020751</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10024384">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10024384</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10028584">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10028584</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10029354">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10029354</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10033661">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10033661</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10038156">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10038156</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10041549">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10041549</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10043554">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10043554</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10044258">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10044258</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10058097">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10058097</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10060862">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10060862</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/MedicalDictionaryForRegulatoryActivities/term/id/10061428">
		<rdf:type rdf:resource="&idmp-meddra;MedDRAIdentifier"/>
		<cmns-txt:hasTextValue>10061428</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/concept/MalignantTumorOfProstateDisorder">
		<rdf:type rdf:resource="&idmp-mprd;IndicationAsDiseaseSymptomProcedure"/>
		<rdf:type rdf:resource="&cmns-cxtdsg;ContextualDesignation"/>
		<rdf:type rdf:resource="&mvf-trm;VocabularyEntry"/>
		<owl:sameAs rdf:resource="&snomed;363346000"/>
		<rdfs:label>Malignant tumor of prostate (disorder)</rdfs:label>
		<cmns-id:isIdentifiedBy rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/id/399068003"/>
		<cmns-ra:isRegisteredIn rdf:resource="https://lookup.snomedtools.org/"/>
		<cmns-txt:hasTextValue>Malignant tumor of prostate (disorder)</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/ISO/NorthAmericanJurisdiction/SNOMED-CT/id/399068003">
		<rdf:type rdf:resource="&cmns-ra;RegisteredIdentifier"/>
		<cmns-txt:hasTextValue>399068003</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spor.ema.europa.eu/v1/lists/100000000001">
		<rdf:type rdf:resource="&idmp-spor;SPORControlledVocabulary"/>
		<rdfs:label>SPOR Age Range</rdfs:label>
		<idmp-spor:hasSPORDomain rdf:resource="&idmp-spor;SPOR-Domain-HumanAndVeterinaryUse"/>
		<idmp-spor:hasSPORVisibility rdf:resource="&idmp-spor;SPOR-DataClassification-Public"/>
		<cmns-dsg:isSignifiedBy>
			<idmp-spor:SPORListName>
				<cmns-txt:hasTextValue>Age Range</cmns-txt:hasTextValue>
				<mvf:hasLanguage rdf:resource="&lcc-639-1;English"/>
			</idmp-spor:SPORListName>
		</cmns-dsg:isSignifiedBy>
		<cmns-id:isIdentifiedBy>
			<idmp-spor:SPORListIdentifier>
				<cmns-txt:hasTextValue>100000000001</cmns-txt:hasTextValue>
			</idmp-spor:SPORListIdentifier>
		</cmns-id:isIdentifiedBy>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spor.ema.europa.eu/v1/lists/100000000001/terms/200000002250">
		<rdf:type rdf:resource="&idmp-spor;SPORControlledVocabularyTerm"/>
		<rdf:type rdf:resource="&idmp-mprd;AgePopulationCharacteristic"/>
		<rdfs:label>SPOR Age Range - Adult and elderly population (&gt;18 years)</rdfs:label>
		<idmp-spor:hasSPORDomain rdf:resource="&idmp-spor;SPOR-Domain-HumanUse"/>
		<idmp-spor:hasSPORShortName>
			<idmp-spor:SPORTermName>
				<cmns-txt:hasTextValue>Adults and elderly</cmns-txt:hasTextValue>
				<mvf:hasLanguage rdf:resource="&lcc-639-1;English"/>
			</idmp-spor:SPORTermName>
		</idmp-spor:hasSPORShortName>
		<idmp-spor:hasSPORTermDescription>
			<idmp-spor:SPORTermDescription>
				<cmns-txt:hasTextValue>Container (usually multidose) consisting of two layers of which one is shaped to contain the individual doses. Strips and unit-dose blisters are excluded.</cmns-txt:hasTextValue>
				<mvf:hasLanguage rdf:resource="&lcc-639-1;English"/>
			</idmp-spor:SPORTermDescription>
		</idmp-spor:hasSPORTermDescription>
		<idmp-spor:hasSPORTermName>
			<idmp-spor:SPORTermName>
				<cmns-txt:hasTextValue>Adult and elderly population (&gt;18 years)</cmns-txt:hasTextValue>
				<mvf:hasLanguage rdf:resource="&lcc-639-1;English"/>
			</idmp-spor:SPORTermName>
		</idmp-spor:hasSPORTermName>
		<idmp-spor:hasSPORVisibility rdf:resource="&idmp-spor;SPOR-DataClassification-Public"/>
		<cmns-col:isIncludedIn rdf:resource="https://spor.ema.europa.eu/v1/lists/100000000001"/>
		<cmns-id:isIdentifiedBy>
			<idmp-spor:SPORTermIdentifier>
				<cmns-txt:hasTextValue>200000002250</cmns-txt:hasTextValue>
			</idmp-spor:SPORTermIdentifier>
		</cmns-id:isIdentifiedBy>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf">
		<rdf:type rdf:resource="&cmns-doc;Document"/>
		<dct:format rdf:resource="http://www.iana.org/assignments/media-types/application/pdf"/>
		<po:contains rdf:resource="&doc-fda;FullPrescribingInformation"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;FullPrescribingInformation">
		<rdf:type rdf:resource="&doco;Chapter"/>
		<po:contains rdf:resource="&doc-fda;Section-1"/>
		<po:contains rdf:resource="&doc-fda;Section-10"/>
		<po:contains rdf:resource="&doc-fda;Section-11"/>
		<po:contains rdf:resource="&doc-fda;Section-12"/>
		<po:contains rdf:resource="&doc-fda;Section-13"/>
		<po:contains rdf:resource="&doc-fda;Section-14"/>
		<po:contains rdf:resource="&doc-fda;Section-16"/>
		<po:contains rdf:resource="&doc-fda;Section-17"/>
		<po:contains rdf:resource="&doc-fda;Section-2"/>
		<po:contains rdf:resource="&doc-fda;Section-3"/>
		<po:contains rdf:resource="&doc-fda;Section-4"/>
		<po:contains rdf:resource="&doc-fda;Section-5"/>
		<po:contains rdf:resource="&doc-fda;Section-6"/>
		<po:contains rdf:resource="&doc-fda;Section-8"/>
		<po:containsAsHeader rdf:resource="&doc-fda;FullPrescribingInformation-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;FullPrescribingInformation-Title">
		<rdf:type rdf:resource="&doco;ChapterTitle"/>
		<idmp-doco:hasText>FULL PRESCRIBING INFORMATION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation">
		<rdf:type rdf:resource="&doco;Chapter"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-Contraindications"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-DosageAndAdministration"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-DosageFormsAndStrengths"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-IndicationsAndUsage"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-Text"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions"/>
		<po:containsAsHeader rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-1"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-2"/>
		<po:containsAsHeader rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-1">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-1-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Most common adverse reactions (≥ 20%) are fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. (6.1)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-2">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-2-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Paragraph-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Most common laboratory abnormalities (≥ 30%) are decreased lymphocytes, decreased hemoglobin, decreased leukocytes, decreased platelets, decreased calcium, and decreased sodium.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-AdverseReactions-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:containsText>ADVERSE REACTIONS</idmp-doco:containsText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-Contraindications">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-Contraindications-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-Contraindications-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-Contraindications-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>None. (4)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-4"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-Contraindications-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:containsText>CONTRAINDICATIONS</idmp-doco:containsText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-DosageAndAdministration">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-DosageAndAdministration-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-DosageAndAdministration-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-DosageAndAdministration-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>• Select patients for treatment using LOCAMETZ® or an approved PSMA-11 imaging agent based on PSMA expression in tumors. (2.2)
• Recommended Dosage: Administer 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses. (2.3)
• Dose interruption, reduction, or permanent discontinuation may be required due to adverse reactions. (2.4)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2.2"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2.3"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2.4"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-DosageAndAdministration-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:containsText>DOSAGE AND ADMINISTRATION</idmp-doco:containsText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-DosageFormAndStrengths">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-DosageFormAndStrengths-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-DosageFormAndStrengths-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-DosageFormAndStrengths-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Injection: 1,000 MBq/mL (27 mCi/mL) in a single-dose vial. (3)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-DosageFormAndStrengths-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:containsText>DOSAGE FORMS AND STRENGTHS</idmp-doco:containsText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-IndicationsAndUsage">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-IndicationsAndUsage-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-IndicationsAndUsage-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-IndicationsAndUsage-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO is a radioligand therapeutic agent indicated for the treatment of
					adult patients with prostate-specific membrane antigen (PSMA)-positive
					metastatic castration-resistant prostate cancer (mCRPC) who have been
					treated with androgen receptor (AR) pathway inhibition and taxane-based
					chemotherapy. (1)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-IndicationsAndUsage-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:containsText>INDICATIONS AND USAGE</idmp-doco:containsText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasTextContent>These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.
PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use
Initial U.S. Approval: 2022</idmp-doco:hasTextContent>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-Title">
		<rdf:type rdf:resource="&doco;ChapterTitle"/>
		<idmp-doco:hasText>HIGHLIGHTS OF PRESCRIBING INFORMATION</idmp-doco:hasText>
		<idmp-doco:hasTextContent>HIGHLIGHTS OF PRESCRIBING INFORMATION</idmp-doco:hasTextContent>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-1"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-2"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-3"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-4"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-5"/>
		<po:containsAsHeader rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-1">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-1-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>• Risk From Radiation Exposure: Minimize radiation exposure during and
after treatment with PLUVICTO consistent with institutional good
radiation safety practices and patient treatment procedures. Ensure patients
increase oral fluid intake and advise patients to void as often as possible to
reduce bladder radiation. (5.1)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-2">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-2-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>• Myelosuppression: Perform complete blood counts. Withhold, reduce dose,
or permanently discontinue PLUVICTO and clinically treat based on
severity. (2.4, 5.2)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2.4"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5.2"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-3">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-3-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>• Renal Toxicity: Advise patients to remain well hydrated and to urinate
frequently. Perform kidney function laboratory tests. Withhold, reduce
dose, or permanently discontinue PLUVICTO based on severity. (2.4, 5.3)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2.4"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5.3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-4">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-4-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>• Embryo-Fetal Toxicity: Can cause fetal harm. Advise male patients with
female partners of reproductive potential to use effective contraception.
(5.4, 8.1, 8.3)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5.4"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-8.1"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-8.3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-5">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-5-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">5</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Paragraph-5-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>• Infertility: PLUVICTO may cause temporary or permanent infertility. (5.5,
8.3)</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5.5"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-8.3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;HighlightsOfPrescribingInformation-WarningsAndPrecautions-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:containsText>WARNINGS AND PRECAUTIONS</idmp-doco:containsText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-1">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-1-Text"/>
		<po:contains rdf:resource="&doc-fda;Section-2-Label"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-1-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;FullPrescribingInformation"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive
					metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway
					inhibition and taxane-based chemotherapy.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-1-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>INDICATIONS AND USAGE</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-2-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-2.1"/>
		<po:contains rdf:resource="&doc-fda;Section-2.2"/>
		<po:contains rdf:resource="&doc-fda;Section-2.3"/>
		<po:contains rdf:resource="&doc-fda;Section-2.4"/>
		<po:contains rdf:resource="&doc-fda;Section-2.5"/>
		<po:contains rdf:resource="&doc-fda;Section-2.6"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-2-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;FullPrescribingInformation"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>1</idmp-doco:hasText>
		<idmp-doco:hasText>2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>DOSAGE AND ADMINISTRATION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.1">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-2.1-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-2.1-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-2.1-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.1-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>2.1</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure [see
					Warnings and Precautions (5.1)]. Use waterproof gloves and effective radiation shielding when handling PLUVICTO.
					Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are
					qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience
					and training have been approved by the appropriate governmental agency authorized to license the use of
					radiopharmaceuticals.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.1-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Important Safety Instructions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.2">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-2.2-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-2.2-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-2.2-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.2-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>2.2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Select patients with previously treated mCRPC for treatment with PLUVICTO using LOCAMETZ or another approved
					PSMA-11 imaging agent based on PSMA expression in tumors. Additional selection criteria were used in the VISION
					study [see Clinical Studies (14)].
					Refer to the prescribing information for the PSMA imaging agent.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-14"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.2-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>2.2 Patient Selection</idmp-doco:hasText>
		<idmp-doco:hasText>Recommended Dosage</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.3">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-2.3-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-2.3-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-2.3-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.3-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>2.3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>The recommended PLUVICTO dosage is 7.4 GBq (200 mCi) intravenously every 6 weeks for up to 6 doses, or until disease progression, or unacceptable toxicity.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.3-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Recommended Dosage</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.4">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-2.4-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-2.4-Text"/>
		<po:contains rdf:resource="&doc-fda;Table-1"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-2.4-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.4-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>2.4</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recommended dosage modifications of PLUVICTO for adverse reactions are provided in Table 1. Management of
					adverse reactions may require temporary dose interruption (extending the dosing interval from every 6 weeks up to every
					10 weeks), dose reduction or permanent discontinuation of treatment with PLUVICTO. If a treatment delay due to an
					adverse reaction persists for &gt; 4 weeks, treatment with PLUVICTO must be discontinued. The dose of PLUVICTO may
					be reduced by 20% to 5.9 GBq (160 mCi) once; do not re-escalate dose. If a patient has further adverse reactions that
					would require an additional dose reduction, treatment with PLUVICTO must be discontinued.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Table-1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.4-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Dosage Modifications for Adverse Reaction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.5">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-2.5-Label"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-2.5-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">5</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.5-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>2.5</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.5-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Preparation and Administration</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.6">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-2.6-Label"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-2.6-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">6</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.6-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>2.6</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-2.6-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Radiation Dosimetry</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-3">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-3-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-3-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-3-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;FullPrescribingInformation"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-3-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Injection: 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan as a clear and colorless to slightly yellow
solution in a single-dose vial.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-3-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>DOSAGE FORMS AND STRENGTHS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-4">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-4-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-4-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-4-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;FullPrescribingInformation"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-4-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>4</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>None.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-4-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>CONTRAINDICATIONS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-5-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-5-Title"/>
		<po:contains rdf:resource="&doc-fda;Section-5.1"/>
		<po:contains rdf:resource="&doc-fda;Section-5.2"/>
		<po:contains rdf:resource="&doc-fda;Section-5.3"/>
		<po:contains rdf:resource="&doc-fda;Section-5.4"/>
		<po:contains rdf:resource="&doc-fda;Section-5.5"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-5-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;FullPrescribingInformation"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">5</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>5</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>WARNINGS AND PRECAUTIONS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.1">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-5.1-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-5.1-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-5.1-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.1-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>5.1</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation
						exposure is associated with an increased risk for cancer.
						Minimize radiation exposure to patients, medical personnel, and household contacts during and after treatment with
						PLUVICTO consistent with institutional good radiation safety practices, patient treatment procedures, Nuclear Regulatory
						Commission patient-release guidance, and instructions to the patient for follow-up radiation protection at home.
						Ensure patients increase oral fluid intake and advise patients to void as often as possible to reduce bladder radiation.
						Before the patient is released, the healthcare provider should explain the necessary radioprotection precautions that the
						patient should follow to minimize radiation exposure to others [see Patient Counseling Information (17)]. Following
						administration of PLUVICTO, advise patients to limit close contact (less than 3 feet) with household contacts for 2 days
						or with children and pregnant women for 7 days. Following administration of PLUVICTO, advise patients to refrain from
						sexual activity for 7 days. Following administration of PLUVICTO, advise patients to sleep in a separate bedroom from
						household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.1-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Risk From Radiation Exposure</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.2">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-5.2-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-5.2-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-5.2-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.2-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>5.2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia,
						and neutropenia. In the VISION study, Grade 3 or 4 decreased hemoglobin (15%), decreased platelets (9%), decreased
						leukocytes (7%), and decreased neutrophils (4.5%) occurred in patients treated with PLUVICTO. Grade ≥ 3 pancytopenia
						occurred in 1.1% (which includes two fatal events) in patients treated with PLUVICTO. Two deaths (0.4%) due to
						intracranial hemorrhage and subdural hematoma in association with thrombocytopenia were observed in patients who
						received PLUVICTO. One death due to sepsis and concurrent neutropenia was observed in patients who received
						PLUVICTO.
						Reference ID: 4957021
						Perform complete blood counts before and during treatment with PLUVICTO. Withhold, reduce dose, or permanently
						discontinue PLUVICTO and clinically treat patients based on the severity of myelosuppression [see Dosage and
						Administration (2.4)].</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-2.4"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.2-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Myelosuppression</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.3">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-5.3-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-5.3-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-5.3-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.3-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>5.3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<dct:relation rdf:resource="&doc-fda;Section-2.4"/>
		<idmp-doco:hasText>PLUVICTO can cause severe renal toxicity. In the VISION study, Grade 3 or 4 acute kidney injury (3%) and increased
						creatinine (0.9%) occurred in patients treated with PLUVICTO.
						Advise patients to remain well hydrated and to urinate frequently before and after administration of PLUVICTO. Perform
						kidney function laboratory tests, including serum creatinine and calculated CLcr, before and during treatment with
						PLUVICTO. Withhold, reduce dose, or permanently discontinue PLUVICTO based on the severity of renal toxicity [see
						Dosage and Administration (2.4)].</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.3-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Renal Toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.4">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-5.4-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-5.4-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-5.4-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.4-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>5.4</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action,
						PLUVICTO can cause fetal harm [see Clinical Pharmacology (12.1)]. No animal studies using lutetium Lu 177
						vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development;
						however, all radiopharmaceuticals, including PLUVICTO, have the potential to cause fetal harm. Advise male patients
						with female partners of reproductive potential to use effective contraception during treatment with PLUVICTO and for
						14 weeks after the last dose [see Use in Specific Populations (8.1, 8.3)].</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-12.1"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-8.1"/>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-8.3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.4-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Embryo-Fetal Toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.5">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-5.5-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-5.5-Text"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-5.5-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">5</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.5-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>5.5</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.5-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO may cause infertility in males. The recommended cumulative dose of 44.4 GBq of PLUVICTO results in a radiation absorbed dose to the testes within the range where PLUVICTO may cause temporary or permanent infertility [see Use in Specific Populations (8.3)].</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-8.3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-5.5-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Infertility</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-6">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-6-Label"/>
		<po:contains rdf:resource="&doc-fda;Section-6-Text"/>
		<po:contains rdf:resource="&doc-fda;Section-6.1"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-6-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;FullPrescribingInformation"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">6</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-6-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>6</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-6-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>The following clinically significant adverse reactions are described elsewhere in the labeling:
• Myelosuppression [see Warnings and Precautions (5.2)]
• Renal Toxicity [see Warnings and Precautions (5.3)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-6-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>ADVERSE REACTIONS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-6.1">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-fda;Section-6.1-Label"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Section-6.1-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-6.1-Label">
		<rdf:type rdf:resource="&doco;SectionLabel"/>
		<idmp-doco:hasText>6.1</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Section-6.1-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Clinical Trials Experience</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1">
		<rdf:type rdf:resource="&doco;Table"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Col-3"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Label"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-10"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-12"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-13"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-14"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-15"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-16"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-17"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-18"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-19"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-3"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-4"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-5"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-6"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-7"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-8"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-9"/>
		<idmp-doco:hasCaption rdf:resource="&doc-fda;Table-1-Caption"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Caption">
		<rdf:type rdf:resource="&idmp-doco;TableCaption"/>
		<idmp-doco:hasText>Recommended Dosage Modifications of PLUVICTO for Adverse Reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-1-Row-1-Col-1"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-1-Row-1-Col-2"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-1-Row-1-Col-3"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<cmns-col:hasIndex>1</cmns-col:hasIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Label">
		<rdf:type rdf:resource="&doco;TableLabel"/>
		<idmp-doco:hasText>Table 1</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-1">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-1-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-1-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-1-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-1-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasText>Adverse reaction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-1-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasText>Severity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-1-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasText>Dose Modification</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-10">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-10-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-10-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-10-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-10-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-10-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-10-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-10-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-10-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement or return to baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-11">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-11-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-11-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-11-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-11-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-11-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent Grade 3 dry mouth after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-11-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-11-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-11-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-12">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-12-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-12-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-12-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-12-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-12-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-12-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Gastrointestinal toxicity
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-12-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-12-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-12-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3 (not amenable to medical intervention)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-12-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-12-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-12-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 2 or baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-13">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-13-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-13-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-13-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-13-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-13-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent Grade ≥ 3 gastrointestinal toxicity after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-13-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-13-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-13-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-14">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-14-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-14-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-14-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-14-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-14-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-14-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Fatigue
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-14-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-14-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-14-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-14-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-14-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-14-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 2 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-15">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-15-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-15-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-15-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-15-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-15-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-15-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Electrolyte or metabolic abnormalities
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-15-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-15-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-15-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-15-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-15-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">15</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-15-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 1 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-16">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-16-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-16-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-16-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-16-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-16-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-16-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>AST or ALT elevation
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-16-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-16-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-16-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>AST or ALT &gt; 5 times ULN in the absence of liver metastases</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-16-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-16-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">16</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-16-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-17">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-17-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-17-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-17-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-17-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-17-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-17-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Other non-hematologic toxicity
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-17-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-17-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-17-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any unacceptable toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-17-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-17-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">17</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-17-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-18">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-18-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-18-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">18</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-18-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-18-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">18</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-18-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any serious adverse reaction that requires treatment delay of &gt; 4 weeks</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-18-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-18-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">18</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-18-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-19">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-19-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-19-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">19</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-19-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-19-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">19</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-19-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any recurrent Grade 3 or 4 or persistent and intolerable Grade 2 adverse reaction after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-19-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-19-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">19</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-19-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-2">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-2-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-2-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-2-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-2-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-2-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-2-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Myelosuppression
(Anemia, thrombocytopenia,leukopenia, or neutropenia)
[see Warnings and Precautions (5.2)]</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-2-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-2-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-2-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-2-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-2-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-2-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 1 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-3">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-3-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-3-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-3-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-3-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-3-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-3-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-3-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-3-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement to Grade 1 or baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-4">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-4-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-4-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-4-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-4-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-4-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent Grade ≥ 3 myelosuppression after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-4-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-4-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-4-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-5">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-5-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-5-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-5-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-5-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-5-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-5-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Renal toxicity
[see Warnings and Precautions (5.3)]</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-5.3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-5-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-5-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-5-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Defined as:
• Confirmed serum creatinine	increase (Grade ≥ 2)
• Confirmed CLcr &lt; 30 mL/min;calculate using Cockcroft-Gaultwith actual body weight</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-5-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-5-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-5-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-6">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-6-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-6-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-6-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-6-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-6-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Defined as:
• Confirmed ≥ 40% increase from baseline serum creatinine and
• Confirmed &gt; 40% decrease from baseline CLcr; calculate using Cockcroft-Gault with actual body weight</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-6-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-6-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-6-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement or return to baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-7">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-7-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-7-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-7-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-7-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-7-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥ 3 renal toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-7-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-7-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-7-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-8">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-8-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-8-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-8-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-8-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-8-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Recurrent renal toxicity after one dose reduction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-8-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-8-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-8-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue PLUVICTO.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-9">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-9-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-9-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-9-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-9-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-9-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-9-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Dry mouth
[see Adverse Reactions (6.1)]</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-fda;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-9-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-9-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-9-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-9-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableCell"/>
		<po:contains rdf:resource="&doc-fda;Table-1-Row-9-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-1-Row-9-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold PLUVICTO until improvement or return to baseline.
Consider reducing PLUVICTO dose by 20% to 5.9 GBq (160 mCi).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3">
		<po:contains rdf:resource="&doc-fda;Table-3-Col-1"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Col-2"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Col-3"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Col-4"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Col-5"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Label"/>
		<idmp-doco:hasCaption rdf:resource="&doc-fda;Table-3-Caption"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Caption">
		<rdf:type rdf:resource="&idmp-doco;TableCaption"/>
		<idmp-doco:hasText>Adverse Reactions (≥ 5%) in Patients with PSMA-positive mCRPC Who Received PLUVICTO Plus BSoC in VISION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-3-Row-1-Column-1"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-3-Row-1-Column-2"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-3-Row-2-Column-2"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-1-Row-2-Column-3"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Col-4">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-3-Row-1-Column-4"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-3-Row-2-Column-4"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Col-5">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:containsAsHeader rdf:resource="&doc-fda;Table-1-Row-2-Column-5"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Label">
		<rdf:type rdf:resource="&doco;TableLabel"/>
		<idmp-doco:hasText>Table 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-1-Column-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowSpan>
		<idmp-doco:hasText>Adverse Reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-1-Column-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Row-1-Column-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableColumnSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnSpan>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-1-Column-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>PLUVICTO Plus BSoC
(N = 529)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-1-Column-4">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Row-1-Column-4-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableColumnSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnSpan>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-1-Column-4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>BSoC
(N = 205)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Row-2-Column-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>All Grades
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Row-2-Column-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grades 3 to 4
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-4">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Row-2-Column-4-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>All Grades
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-5">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-fda;Table-3-Row-2-Column-5-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-fda;Table-3-Row-2-Column-5-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grades 3 to 4
(%)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/documents/product-information/pluvicto-epar-product-information_en.pdf">
		<rdf:type rdf:resource="&cmns-doc;Document"/>
		<dct:format rdf:resource="http://www.iana.org/assignments/media-types/application/pdf"/>
		<dct:title>Pluvicto EPAR Product Information</dct:title>
		<po:contains rdf:resource="&doc-ema;Annex-1"/>
		<po:contains rdf:resource="&doc-ema;Annex-2"/>
		<po:contains rdf:resource="&doc-ema;Annex-3"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-1">
		<rdf:type rdf:resource="&doco;Chapter"/>
		<po:contains rdf:resource="&doc-ema;Section-1"/>
		<po:contains rdf:resource="&doc-ema;Section-2"/>
		<po:contains rdf:resource="&doc-ema;Section-3"/>
		<po:contains rdf:resource="&doc-ema;Section-4"/>
		<po:contains rdf:resource="&doc-ema;Section-5"/>
		<po:contains rdf:resource="&doc-ema;Section-6"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Annex-1-SubTitle"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Annex-1-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-1-SubTitle">
		<rdf:type rdf:resource="&doco;ChapterSubTitle"/>
		<idmp-doco:hasText>SUMMARY OF PRODUCT CHARACTERISTICS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-1-Title">
		<rdf:type rdf:resource="&doco;ChapterTitle"/>
		<idmp-doco:hasText>ANNEX I</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-2">
		<rdf:type rdf:resource="&doco;Chapter"/>
		<po:contains rdf:resource="&doc-ema;Annex-2"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Annex-2-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-2-Title">
		<rdf:type rdf:resource="&doco;ChapterTitle"/>
		<idmp-doco:hasText>ANNEX II</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-3">
		<rdf:type rdf:resource="&doco;Chapter"/>
		<po:contains rdf:resource="&doc-ema;Annex-3"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Annex-3-SubTitle"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Annex-3-Title"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-3-SubTitle">
		<rdf:type rdf:resource="&doco;ChapterSubTitle"/>
		<idmp-doco:hasText>LABELLING AND PACKAGE LEAFLET</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Annex-3-Title">
		<rdf:type rdf:resource="&doco;ChapterTitle"/>
		<idmp-doco:hasText>ANNEX III</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Figure-1">
		<rdf:type rdf:resource="&doco;Figure"/>
		<po:contains rdf:resource="&doc-ema;Figure-1-Label"/>
		<idmp-doco:hasCaption rdf:resource="&doc-ema;Figure-1-Caption"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Figure-1-Caption">
		<rdf:type rdf:resource="&idmp-doco;FigureCaption"/>
		<idmp-doco:hasText>Kaplan-Meier plot of OS in VISION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Figure-1-Label">
		<rdf:type rdf:resource="&doco;FigureLabel"/>
		<idmp-doco:hasText>Figure 1</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Figure-2">
		<rdf:type rdf:resource="&doco;Figure"/>
		<po:contains rdf:resource="&doc-ema;Figure-2-Label"/>
		<idmp-doco:hasCaption rdf:resource="&doc-ema;Figure-2-Caption"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Figure-2-Caption">
		<rdf:type rdf:resource="&idmp-doco;FigureCaption"/>
		<idmp-doco:hasText>Kaplan-Meier plot of BICR-assessed rPFS in VISION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Figure-2-Label">
		<rdf:type rdf:resource="&doco;FigureLabel"/>
		<idmp-doco:hasText>Figure 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-1">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-1-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-1-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Pluvicto 1 000 MBq/mL solution for injection/infusion</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-1-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>NAME OF THE MEDICINAL PRODUCT</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-2">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-2-ExcipientWithKnownEffect"/>
		<po:contains rdf:resource="&doc-ema;Section-2-PhysicalCharacteristics"/>
		<po:contains rdf:resource="&doc-ema;Section-2-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-2-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-2-ExcipientWithKnownEffect">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-2-ExcipientWithKnownEffect-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-2-ExcipientWithKnownEffect-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-2-ExcipientWithKnownEffect-Text">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Each mL of solution contains up to 0.312 mmol (7.1 mg) of sodium. Each vial contains up to
88.75 mg of sodium.
For the full list of excipients, see section 6.1.</idmp-doco:hasText>
		<idmp-doco:hasText>Excipient with known effect</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-2-PhysicalCharacteristics">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-2-PhysicalCharacteristics-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-2-PhysicalCharacteristics-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-2-PhysicalCharacteristics-Text">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Lutetium-177 decays to a stable hafnium-177 with a physical half-life of 6.647 days by emitting
beta-minus radiation with a maximum energy of 0.498 MeV (79%) and photon radiation (γ) of
0.208 MeV (11%) and 0.113 MeV (6.4%).</idmp-doco:hasText>
		<idmp-doco:hasText>Physical characteristics</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>One mL of solution contains 1 000 MBq of lutetium (177Lu) vipivotide tetraxetan at the date and time
of calibration.
The total amount of radioactivity per single-dose vial is 7 400 MBq ± 10% at the date and time of
administration. Given the fixed volumetric activity of 1 000 MBq/mL at the date and time of
calibration, the volume of the solution in the vial can range from 7.5 mL to 12.5 mL in order to
provide the required amount of radioactivity at the date and time of administration.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-2-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>QUALITATIVE AND QUANTITATIVE COMPOSITION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-3">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-3-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-3-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Solution for injection/infusion.
Clear, colourless to slightly yellow solution, pH: 4.5 to 7.0.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-3-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>PHARMACEUTICAL FORM</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.1"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2"/>
		<po:contains rdf:resource="&doc-ema;Section-4.3"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4"/>
		<po:contains rdf:resource="&doc-ema;Section-4.5"/>
		<po:contains rdf:resource="&doc-ema;Section-4.6"/>
		<po:contains rdf:resource="&doc-ema;Section-4.7"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8"/>
		<po:contains rdf:resource="&doc-ema;Section-4.9"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>CLINICAL PARTICULARS</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.1">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.1-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.1-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor
					(AR) pathway inhibition is indicated for the treatment of adult patients with progressive
					prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer
					(mCRPC) who have been treated with AR pathway inhibition and taxane-based chemotherapy (see
					section 5.1).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.1-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Therapeutic indications</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-MethodOfAdministration"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-PatientIdentification"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-Posology"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.2-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-ImportantSafetyInstructions">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-1"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-2"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-1">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-1-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Pluvicto should be administered only by persons authorised to handle radiopharmaceuticals in 
designated clinical settings (see section 6.6) and after evaluation of the patient by a qualified
physician.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6.6"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-2">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-2-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2-ImportantSafetyInstructions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-ImportantSafetyInstructions-Paragraph-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Radiopharmaceuticals, including Pluvicto, should be used by or under the control of healthcare
professionals who are qualified by specific training and experience in the safe use and handling of
radiopharmaceuticals, and whose experience and training have been approved by the appropriate
governmental agency authorised to license the use of radiopharmaceuticals.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-ImportantSafetyInstructions-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Important safety instructions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-MethodOfAdministration">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-MethodOfAdministration-AdministrationInstructions"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-PatientIdentification">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.2-PatientIdentification-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-PatientIdentification-Text">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Patient identification</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-Posology-DoseModificationForAdverseReactions"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-Posology-SpecialPopulations"/>
		<po:contains rdf:resource="&doc-ema;Section-4.2-Posology-TreatmentMonitoring"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.2-Posology-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology-DoseModificationForAdverseReactions">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Table-1"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.2-Posology-DoseModificationForAdverseReactions-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2-Posology"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology-DoseModificationForAdverseReactions-Text">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Dose modifications for adverse reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology-SpecialPopulations">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.2-Posology-SpecialPopulations-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2-Posology"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology-SpecialPopulations-Text">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Special populations</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology-Text">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Posology</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology-TreatmentMonitoring">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.2-Posology-TreatmentMonitoring-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2-Posology"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Posology-TreatmentMonitoring-Text">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Treatment monitoring</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.2-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Posology and method of administration</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.3">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.3-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.3-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6.1"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.3-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Contraindications</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.4">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-ContraceptionInMales"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-Fertility"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-IndividualBenefitRiskJustification"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-Myelosuppression"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-RenalHepaticImpairment"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-RenalToxicity"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-RiskFromRadiationExposure"/>
		<po:contains rdf:resource="&doc-ema;Section-4.4-SpecificWarnings"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.4-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.4-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Special warnings and precautions for use</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.5">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.5-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.5-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">5</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.5-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>No clinical drug interaction studies were performed.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.5-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Interaction with other medicinal products and other forms of interaction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.6">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.6-BreastFeeding"/>
		<po:contains rdf:resource="&doc-ema;Section-4.6-ContraceptionInMales"/>
		<po:contains rdf:resource="&doc-ema;Section-4.6-Fertility"/>
		<po:contains rdf:resource="&doc-ema;Section-4.6-Pregnancy"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.6-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">6</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.6-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Fertility, pregnancy and lactation</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.7">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.7-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.7-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">7</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.7-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Pluvicto may have a minor influence on the ability to drive and use machines.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.7-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Effects on ability to drive and use machines</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-TabulatedListOfAdverseReactions"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">8</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-ReportingOfSuspectedAdverseReactions"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-SecondPrimaryMalignancies"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-1"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-2"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-1">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-1-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>In the VISION study, myelosuppression occurred more frequently in patients who received Pluvicto
plus BSoC compared to patients who received BSoC alone (all grades/grade ≥3): anaemia
(31.8%/12.9%) versus (13.2%/4.9%); thrombocytopenia (17.2%/7.9%) versus (4.4%/1.0%);
leukopenia (12.5%/2.5%) versus (2.0%/0.5%); lymphopenia (14.2%/7.8%) versus (3.9%/0.5%);
neutropenia (8.5%/3.4%) versus (1.5%/0.5%); pancytopenia (1.5%/1.1%) versus (0%/0%) including
two fatal events of pancytopenia in patients who received Pluvicto plus BSoC; and bicytopenia
(0.2%/0.2%) versus (0%/0%).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-2">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-2-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Paragraph-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Myelosuppression adverse reactions that led to permanent discontinuation in ≥0.5% of patients who
received Pluvicto plus BSoC included: anaemia (2.8%), thrombocytopenia (2.8%), leukopenia (1.3%),
neutropenia (0.8%) and pancytopenia (0.6%). Myelosuppression adverse reactions that led to dose
interruptions/dose reductions in ≥0.5% of patients who received Pluvicto plus BSoC included:
anaemia (5.1%/1.3%), thrombocytopenia (3.6%/1.9%), leukopenia (1.5%/0.6%) and neutropenia
(0.8%/0.6%).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Myelosuppression-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Myelosuppression</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-1"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-2"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-1">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-1-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>In the VISION study, renal toxicity occurred more frequently in patients who received Pluvicto plus
BSoC compared to patients who received BSoC alone (all grades/grades 3 to 4): blood creatinine
increased (5.3%/0.2%) versus (2.4%/0.5%); acute kidney injury (3.6%/3.0%) versus (3.9%/2.4%);
renal failure (0.2%/0%) versus (0%/0%); and blood urea increased (0.2%/0%) versus (0%/0%).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-2">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-2-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Paragraph-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Renal adverse reactions that led to permanent discontinuation in ≥0.2% of patients who received
Pluvicto plus BSoC included: blood creatinine increased (0.2%). Renal adverse reactions that led to
dose interruptions/dose reductions in ≥0.2% of patients who received Pluvicto plus BSoC included:
blood creatinine increased (0.2%/0.4%) and acute kidney injury (0.2%/0%).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-RenalToxicity-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Renal toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-ReportingOfSuspectedAdverseReactions">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-ReportingOfSuspectedAdverseReactions-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-ReportingOfSuspectedAdverseReactions-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-ReportingOfSuspectedAdverseReactions-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-ReportingOfSuspectedAdverseReactions-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Reporting of suspected adverse reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-SecondPrimaryMalignancies">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-SecondPrimaryMalignancies-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-SecondPrimaryMalignancies-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-SecondPrimaryMalignancies-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Exposure to ionising radiation is linked with cancer induction and a potential for development of
hereditary defects. The radiation dose resulting from therapeutic exposure may result in higher
incidence of cancer and mutations. In all cases it is necessary to ensure that the risks of the radiation
are less than from the disease itself. As Pluvicto contributes to a patient’s overall long-term radiation
exposure, which is associated with an increased risk for cancer (see section 4.4), a potential risk of
second primary malignancies cannot be ruled out for radiopharmaceuticals such as Pluvicto. At the
time of the VISION primary analysis (cut-off date 27-Jan-2021), cases of squamous cell carcinoma
(4 patients; 0.8%) and basal cell carcinoma, malignant melanoma and squamous cell carcinoma of the
skin (1 patient each; 0.2% each) were reported in patients who received Pluvicto plus BSoC.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-SecondPrimaryMalignancies-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Second primary malignancies</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-DescriptionOfSelectedAdverseReactions-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Description of selected adverse reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-SummaryOfSafetyProfile">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-1"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-2"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-1">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-1-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Unless otherwise stated, the frequency of listed adverse reactions is based on data from the VISION study in which 529 patients received at least one dose of 7 400 MBq (median number of doses was five).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-2">
		<rdf:type rdf:resource="&doco;Paragraph"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-2-Text"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8-SummaryOfSafetyProfile"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Paragraph-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>The most common adverse reactions include: fatigue (43.1%), dry mouth (39.3%), nausea (35.3%), anaemia (31.8%), decreased appetite (21.2%) and constipation (20.2%).
		The most common grade 3 to 4 adverse reactions include: anaemia (12.9%), thrombocytopenia (7.9%), lymphopenia (7.8%) and fatigue (5.9%).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-SummaryOfSafetyProfile-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Summary of safety profile</idmp-doco:hasText>
		<idmp-doco:hasText>Tabulated list of adverse reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-TabulatedListOfAdverseReactions">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.8-TabulatedListOfAdverseReactions-Text"/>
		<po:contains rdf:resource="&doc-ema;Table-2"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.8-TabulatedListOfAdverseReactions-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.8"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-TabulatedListOfAdverseReactions-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Adverse reactions (Table 2) are listed by MedDRA system organ class. Within each system organ
class, the adverse reactions are ranked by frequency, with the most frequent reactions first. In addition,
the corresponding frequency category for each adverse reaction is based on the following convention
(CIOMS III): very common (≥1/10); common (≥1/100 to &lt;1/10); uncommon (≥1/1 000 to &lt;1/100);
rare (≥1/10 000 to &lt;1/1 000); very rare (&lt;1/10 000).</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.8-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Undesirable effects</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.9">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-4.9-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-4.9-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">9</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.9-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>In the event of administration of a radiation overdose with Pluvicto, the absorbed dose to the patient
should be reduced where possible by increasing the elimination of the radionuclide from the body by
frequent micturition or by forced diuresis and frequent bladder voiding. It might be helpful to estimate
the effective dose that was applied.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-4.9-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Overdose</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.1"/>
		<po:contains rdf:resource="&doc-ema;Section-6.2"/>
		<po:contains rdf:resource="&doc-ema;Section-6.3"/>
		<po:contains rdf:resource="&doc-ema;Section-6.4"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">6</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Shelf life</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.1">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.1-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6.1-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Acetic acid
Sodium acetate
Gentisic acid
Sodium ascorbate
Pentetic acid
Water for injections</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.1-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>List of excipients</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.2">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.2-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6.2-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>This medicinal product must not be mixed with other medicinal products except those mentioned in
sections 4.2 and 12.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-ema;Section-12"/>
		<cmns-doc:refersTo rdf:resource="&doc-ema;Section-4.2"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.2-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Incompatibilities</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.3">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.3-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6.3-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>120 hours (5 days) from the date and time of calibration.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.3-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Shelf life</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.4">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.4-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6.4-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">4</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.4-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Do not freeze.
Store in the original package in order to protect from ionising radiation (lead shielding).
Storage of radiopharmaceuticals should be in accordance with national regulations on radioactive
materials.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.4-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Special precautions for storage</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.5">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.5-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6.5-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">5</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.5-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Clear, colourless type I glass vial, closed with a bromobutyl rubber stopper and aluminium seal.
Each vial contains a volume of solution that can range from 7.5 mL to 12.5 mL corresponding to a
radioactivity of 7 400 MBq ±10% at the date and time of administration.
The vial is enclosed within a lead container for protective shielding.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.5-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>Nature and contents of container</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.6">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.6-GeneralWarning"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6.6-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">6</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.6-GeneralWarning">
		<rdf:type rdf:resource="&doco;Section"/>
		<po:contains rdf:resource="&doc-ema;Section-6.6-GeneralWarning-Text"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Section-6.6-GeneralWarning-Title"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Section-6.6"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.6-GeneralWarning-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Radiopharmaceuticals should be received, used and administered only by authorised persons in
designated clinical settings. Their receipt, storage, use, transfer and disposal are subject to the
regulations and/or appropriate licences of the competent official organisation.
Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and
pharmaceutical quality requirements. Appropriate aseptic precautions should be taken.
For instructions on preparation of the medicinal product before administration, see section 12.
If at any time in the preparation of this medicinal product the integrity of the lead container or the vial
is compromised it should not be used.
Administration procedures should be carried out in a way to minimise risk of contamination of the
medicinal product and irradiation of the operators. Adequate shielding is mandatory.
19
The administration of radiopharmaceuticals creates risks for other persons from external radiation or
contamination from spill of urine, vomiting, etc. Radiation protection precautions in accordance with
national regulations must therefore be taken.
This preparation is likely to result in a relatively high radiation dose to most patients. The
administration of Pluvicto may result in significant environmental hazard. This may be of concern to
the immediate family of those individuals undergoing treatment or the general public depending on the
level of activity administered. Suitable precautions in accordance with national regulations should be
taken concerning the activity eliminated by the patients in order to avoid any contaminations.
Lutetium-177 for Pluvicto may be prepared using two different sources of stable isotopes (either
lutetium-176 or ytterbium-176). Lutetium-177 for Pluvicto prepared using the stable isotope
lutetium-176 (“carrier added”) requires special attention with regard to waste management due to the
presence of the long-lived metastable lutetium-177 (177mLu) impurity with a half-life of 160.4 days.
Lutetium-177 for Pluvicto is prepared using ytterbium-176 (“non-carrier added”) unless otherwise
communicated on the product batch release certificate. The user must consult the product batch release
certificate provided before using Pluvicto to ensure appropriate waste management.
Any unused medicinal product or waste material should be disposed of in accordance with local
requirements.</idmp-doco:hasText>
		<cmns-doc:refersTo rdf:resource="&doc-ema;Section-12"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Section-6.6-Title">
		<rdf:type rdf:resource="&doco;SectionTitle"/>
		<idmp-doco:hasText>General warning</idmp-doco:hasText>
		<idmp-doco:hasText>Special precautions for disposal and other handling</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1">
		<rdf:type rdf:resource="&doco;Table"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Col-3"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Label"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-10"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-11"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-12"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-13"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-14"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-4"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-5"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-6"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-7"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-8"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-9"/>
		<idmp-doco:hasCaption rdf:resource="&doc-ema;Table-1-Caption"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">1</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Caption">
		<rdf:type rdf:resource="&idmp-doco;TableCaption"/>
		<idmp-doco:hasText>Recommended dose modifications of Pluvicto for adverse reactions</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-1"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Table-1-Row-1-Col-1"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-2"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Table-1-Row-1-Col-2"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumn"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-3"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-3"/>
		<po:containsAsHeader rdf:resource="&doc-ema;Table-1-Row-1-Col-3"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Label">
		<rdf:type rdf:resource="&doco;TableLabel"/>
		<idmp-doco:hasText>Table 1</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-1">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-1-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-1-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-1-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-1-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-1-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-1-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Adverse reaction</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-1-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-1-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-1-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Severity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-1-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableColumnHeaderCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-1-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-1-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>&gt;Dose modification</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-10">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-10-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-10-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-10-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-10-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-10-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-10-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Fracture in weight-bearing bones</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-10-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-10-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-10-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-10-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-10-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">10</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-10-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until the fracture has been
adequately stabilised/treated and ECOG
performance status has stabilised.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-11">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-11-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-11-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-11-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-11-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-11-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-11-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Fatigue</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-11-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-11-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-11-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-11-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-11-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">11</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-11-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement to Grade 2 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-12">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-12-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-12-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-12-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-12-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-12-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-12-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Electrolyte or metabolic abnormalities</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-12-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-12-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-12-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-12-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-12-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">12</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-12-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement to Grade 1 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-13">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-13-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-13-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-13-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-13-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-13-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-13-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Non-haematological toxicity (clinically significant, not otherwise stated)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-13-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-13-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-13-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-13-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-13-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">13</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-13-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement to Grade 1 or baseline.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-14">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-14-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-14-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-14-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-14-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-14-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-14-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>AST or ALT elevation</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-14-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-14-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-14-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>AST or ALT &gt;5 times ULN in the absence of liver metastases</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-14-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-14-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">14</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-14-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue Pluvicto.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-2">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-2-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-2-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Dry mouth</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-2-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-2-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-2-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-2-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-2-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Reduce Pluvicto does by 20%.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-3">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-3-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-3-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Gastrointestinal toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-3-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-3-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥3 (not amenable to medical intervention)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-3-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-3-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-3-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement to grade 2 or baseline.
Reduce Pluvicto dose by 20%.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-4">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-4-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-4-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-4-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-4-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-4-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-4-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Anaemia,
thrombocytopenia,
leukopenia,
neutropenia,
pancytopenia</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-4-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-4-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-4-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-4-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-4-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">4</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-4-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement to
grade 1 or baseline.
Manage as deemed appropriate. The use of
growth factors is permitted but should be
discontinued once improved to grade 1 or
baseline. Checking haematinic levels (iron,
B12 and folate) and providing
supplementation is advocated. Transfusions
may be given as clinically indicated.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-5">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-5-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-5-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-5-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-5-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-5-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Grade ≥3</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-5-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-5-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">5</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-5-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement to
grade 1 or baseline.
Reduce Pluvicto dose by 20%.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-6">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-6-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-6-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-6-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-6-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-6-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
		<idmp-doco:hasTableRowSpan rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableRowSpan>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-6-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Renal toxicity</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-6-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-6-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-6-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Defined as:
• Confirmed serum
creatinine increase
(grade ≥2)
• Confirmed CLcr
&lt;50 mL/min; calculate
using Cockcroft-Gault
with actual body weight</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-6-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-6-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">6</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-6-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-7">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-7-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-7-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-7-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-7-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-7-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Defined as:
• Confirmed ≥40%
increase from baseline
serum creatinine
and
• Confirmed &gt;40%
decrease from baseline
CLcr; calculate using
Cockcroft-Gault with
actual body weight</idmp-doco:hasText>
		<idmp-doco:hasText>Recurrent renal toxicity (grade ≥3)</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-7-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-7-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">7</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-7-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until improvement or return to baseline.
Reduce Pluvicto dose by 20%.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-8">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-8-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-8-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger"></idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-8-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-7-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-8-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-8-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">8</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-8-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Permanently discontinue Pluvicto.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-9">
		<rdf:type rdf:resource="&idmp-doco;TableRow"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-9-Col-1"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-9-Col-2"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-9-Col-3"/>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-9-Col-1">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-9-Col-1-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">1</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-9-Col-1-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Spinal cord compression</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-9-Col-2">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-9-Col-2-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">2</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-9-Col-2-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Any</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-9-Col-3">
		<rdf:type rdf:resource="&idmp-doco;TableBodyCell"/>
		<po:contains rdf:resource="&doc-ema;Table-1-Row-9-Col-3-Text"/>
		<idmp-doco:hasTableColumnIndex rdf:datatype="&xsd;positiveInteger">3</idmp-doco:hasTableColumnIndex>
		<idmp-doco:hasTableRowIndex rdf:datatype="&xsd;positiveInteger">9</idmp-doco:hasTableRowIndex>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-1-Row-9-Col-3-Text">
		<rdf:type rdf:resource="&po;TextualElement"/>
		<idmp-doco:hasText>Withhold Pluvicto until the compression has
been adequately treated and any neurological
sequela have stabilised and ECOG
performance status has stabilised.</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-2">
		<rdf:type rdf:resource="&doco;Table"/>
		<po:contains rdf:resource="&doc-ema;Table-2-Label"/>
		<idmp-doco:hasCaption rdf:resource="&doc-ema;Table-2-Caption"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">2</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-2-Caption">
		<rdf:type rdf:resource="&idmp-doco;TableCaption"/>
		<idmp-doco:hasText>Adverse reactions occurring at a higher incidence in patients who received Pluvicto plus BSoC compared to BSoC alone in VISION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-2-Label">
		<rdf:type rdf:resource="&doco;TableLabel"/>
		<idmp-doco:hasText>Table 2</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-3">
		<rdf:type rdf:resource="&doco;Table"/>
		<po:contains rdf:resource="&doc-ema;Table-3-Label"/>
		<idmp-doco:hasCaption rdf:resource="&doc-ema;Table-3-Caption"/>
		<cmns-strcol:hasIndexValue>
			<cmns-strcol:IndexValue>
				<cmns-doc:refersTo rdf:resource="&doc-ema;Annex-1"/>
				<cmns-qtu:hasNumericValue rdf:datatype="&xsd;positiveInteger">3</cmns-qtu:hasNumericValue>
			</cmns-strcol:IndexValue>
		</cmns-strcol:hasIndexValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-3-Caption">
		<rdf:type rdf:resource="&idmp-doco;TableCaption"/>
		<idmp-doco:hasText>Efficacy results in VISION</idmp-doco:hasText>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&doc-ema;Table-3-Label">
		<rdf:type rdf:resource="&doco;TableLabel"/>
		<idmp-doco:hasText>Table 3</idmp-doco:hasText>
	</owl:NamedIndividual>

</rdf:RDF>